Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

1H-Imidazo[4,5-c]quinolin-4-amine derivatives have been synthesized as allosteric modulators of the human A3 adenosine receptor (AR). Structural modifications were made at the 4-amino and 2 positions. The compounds were tested in both binding and functional assays, and many were found to be allosteric enhancers of the action of A3AR agonists by several different criteria. First, a potentiation of the maximum efficacy of the agonist Cl-IB-MECA was observed for numerous derivatives. Also, a number of these compounds decreased the rate of dissociation of the agonist [125I]I-AB-MECA from the A3AR. Most prominently, compound 43 (LUF6000) was found to enhance agonist efficacy in a functional assay by 45% and decrease dissociation rate similarly without influencing agonist potency. The structural requirements for allosteric enhancement at the A3AR were distinct from the requirements to inhibit equilibrium binding. Thus, we have prepared allosteric enhancers of the human A3AR that have an improved allosteric effect in comparison to the inhibition of equilibrium binding at the orthosteric site.

[1]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[2]  J. Linden,et al.  Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. , 2003, Molecular pharmacology.

[3]  J. Fergus,et al.  Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[4]  Kenneth A Jacobson,et al.  Allosteric modulation of the adenosine family of receptors. , 2005, Mini reviews in medicinal chemistry.

[5]  J. Changeux,et al.  Allosteric Mechanisms of Signal Transduction , 2005, Science.

[6]  C. Langmead,et al.  Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.

[7]  J. Eisenach,et al.  Allosteric Adenosine Receptor Modulation Reduces Hypersensitivity Following Peripheral Inflammation by a Central Mechanism , 2003, Journal of Pharmacology and Experimental Therapeutics.

[8]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[9]  Manfred Thiel,et al.  Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. , 2004, Annual review of immunology.

[10]  A. IJzerman,et al.  Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. , 1999, Journal of medicinal chemistry.

[11]  Willem Soudijn,et al.  Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. , 2004, Drug discovery today.

[12]  F. Ehlert.  Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  R. C. Young,et al.  Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase. , 1990, Journal of medicinal chemistry.

[14]  N. Nagano.  Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. , 2006, Pharmacology & therapeutics.

[15]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[16]  Z. Gao,et al.  Competitive and allosteric binding of 2 alpha-DHET and its optical isomers to rat cardiac muscarinic receptors. , 1995, European journal of pharmacology.

[17]  L. Belardinelli,et al.  Substituted 1,3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors. , 1994, Journal of medicinal chemistry.

[18]  K. Jacobson,et al.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. , 2001, Molecular pharmacology.

[19]  S. Lazareno,et al.  Allosterism at muscarinic receptors: ligands and mechanisms. , 2005, Mini reviews in medicinal chemistry.

[20]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[21]  J. E. Christian,et al.  Quinoline Derivatives from 3-Nitro-4-hydroxyquinoline1 , 1947 .

[22]  S. Childers,et al.  Allosteric modulation of adenosine A1 receptor coupling to G‐proteins in brain , 2005, Journal of neurochemistry.

[23]  J. Shryock,et al.  Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). , 2004, Current topics in medicinal chemistry.

[24]  J. Schnermann,et al.  A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. , 2005, The Journal of clinical investigation.

[25]  Adriaan P IJzerman,et al.  Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. , 2002, Molecular pharmacology.

[26]  K. Jacobson,et al.  2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. , 2004, Biochemical pharmacology.

[27]  B. Fredholm,et al.  A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. , 1990, Analytical biochemistry.

[28]  L. Bačáková,et al.  Activation of muscarinic acetylcholine receptors via their allosteric binding sites. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[30]  D. Hall,et al.  Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.

[31]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[32]  Kenneth A Jacobson,et al.  Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. , 2003, Molecular pharmacology.

[33]  C. Müller,et al.  Adenosine receptor agonists: from basic medicinal chemistry to clinical development , 2003, Expert opinion on emerging drugs.